Skip to main content
Novartis
language-selector-globe
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | English
Novartis Foundation | English
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Board of Directors 
        • Giovanni Caforio 
        • Simon Moroney 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Elizabeth McNally 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 
        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Patrick Horber 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Lutz Hegemann 
        • Kees Roks 
        • Michelle Weese 
      • Products 
      • Therapeutic areas 
        • Cardiovascular, renal and metabolic 
        • Immunology 
        • Neuroscience 
        • Oncology 
      • People and culture 
      • Inclusion 
        • Promoting inclusion 
        • Building belonging 
        • Parental leave 
      • Novartis Gene Therapies 
      • Manufacturing 
      • Quality 
        • Audit program 
        • Novartis quality management system (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Awards and recognition 
      Mother and daughter cuddling on a bed in a kids room

      About

      Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Diseases 
      • Patient organization funding 
      • Patients perspectives stories 
      Adult daughter talking to her senior parents on a bench in a park

      Patients and caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare professionals 
      • Medical congresses and events 
        • ASCO Annual Meeting 
      • Products 
      • Novartis pipeline 
      • Managed access programs 
        • Zolgensma® Global Managed Access Program (gMAP) 
      • Novartis external funding 
      • Healthcare professional resources by country 
      • Investigator-initiated trials / studies 
      • Novartis medical information 
        • Submit medical enquiry 
      Doctor discussing illness with patient in an office

      Healthcare professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research and development 
      • Technology platforms 
      • Research disease areas 
        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
      • Novartis pipeline 
      • Research collaborations 
      • Collaborations 
      A female research scientist in a lab looking at a sample

      Research & development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 
      • Access 
        • Creating sustainable business models 
        • Value-based pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis access principles 
        • Novartis oncology access 
        • Patents and licensing 
      • Environmental sustainability 
        • Climate 
        • Nature - Waste 
        • Nature - Water 
      • Ethics, risk and compliance 
        • Ethical behavior 
        • Compliance 
        • Human rights 
        • Learning and engagement 
        • Integrated risk assurance 
      • Global health 
        • Pandemic preparedness 
        • Avoidable blindness 
        • Chagas disease 
        • Leprosy 
        • Malaria 
        • Sickle cell disease (SCD) 
        • Novartis Foundation 
      • Inclusion 
      • ESG index 
      • Reporting and transparency hub 
        • ESG rating performance 
        • Targets 
        • Patient organization funding 
        • Payments to healthcare professionals 
        • Public policy 
        • A living wage 
        • A safe workplace 
        • Animal research 
      Family and friends having a party at home

      Environmental, social and governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 
      • Event calendar 
      • Financial data 
        • Novartis annual results 
        • Novartis quarterly results 
        • Novartis SEC filings 
        • Product sales 
        • Fixed-income securities 
        • Expected currency impact 
      • Share data and analysis 
        • Share monitor 
        • Dividend information 
        • Share ownership 
        • Share overview 
        • Return on investment calculator 
      • Shareholder information 
        • General Meetings 
        • American Depositary Receipts (ADR) 
        • Share buyback 
        • Frequently asked questions 
      • Company overview 
        • Corporate governance 
      • Reporting and transparency hub 
        • Reporting archive 
        • ESG rating performance 
        • Publications order form 
      • ESG 
      Business woman working on her laptop in a bright atmosphere

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 
      • News archive  
      • Media library  
      • Stories 
      • Subscribe 
      • Events 
      Overhead view of a meeting room with people in the foreground and screens in the background

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 
      • Career search 
      • Our business functions 
        • Careers in research and development 
        • Careers in operations 
        • Careers in commercial and sales 
        • Careers in global functions 
      • Why Novartis 
      • Career hub 
        • Temporary contracts 
      • Early careers 
        • Graduates 
        • Students 
        • US Biomedical Research internship programs 
        • Community exploration and learning lab (CELL) 
      Two business people

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical trials 
    • Partnering 
    • Supplier portal 
    • Report side effects 
    • Contacts 
    Grandmother, mother and daughter smiling and laughing on a beach

    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Stories

Story Navigation
  • All Topics
  • Discovery
  • From Our Labs
  • Patient Perspectives
  • Access to Healthcare
  • People & Culture
icon
  • A highly trained Novartis specialist dresses in full personal protective equipment to work on the radioligand therapy production line
    From Our Labs
    CancerDrug DevelopmentOncologyReimagine MedicineTargeted Therapy
    Apr 2, 2024

    Drug delivery, service delivery, and the future of cancer care

    State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.

    From Our Labs
  • Two climbers working together to climb up a rock face.
    From Our Labs
    CancerClinical ResearchInnovationOncologyScientific Research
    Dec 1, 2021

    When it comes to cancer, there’s power in a good partner

    Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

    From Our Labs
  • Coronavirus
    From Our Labs
    COVID-19Disease EradicationInnovationScientific Research
    Jul 20, 2021

    A visual tour of scientific strategies for combating coronavirus

    Researchers around the world are collaborating to provide solutions to immediate and future challenges.

    From Our Labs
  • Wendi Yajnik, Global Head of Academic Partnerships and External Innovation for research
    From Our Labs
    Drug DiscoveryEmerging TechnologyInnovationNovartis Institutes for BioMedical ResearchPostdoc Program
    Sep 28, 2021

    Advancing medicine through collaboration

    In Wendi Yajnik’s quest to find new technologies that could transform medicine, relationships are priority No. 1.

    From Our Labs
  • Special instrument controlled by a production associate
    From Our Labs
    CancerOncologyTargeted TherapyDrug DevelopmentDrug Design
    Jul 20, 2021

    Turning the power of nuclear technology into a medical force

    Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.

    From Our Labs
  • MRI technology reveals cartilage in knees
    From Our Labs
    InnovationNovartis Institutes for BioMedical ResearchScientific Research
    Sep 28, 2021

    Seeing through knees in quest to alleviate osteoarthritis

    Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.

    From Our Labs
  • A Cell Processing Specialist at work in Novartis’ new cell and gene production facility in Stein, Switzerland.
    From Our Labs
    Cell and Gene TherapyFuture of HealthcareInnovationOncologyWorking at Novartis
    Jul 19, 2021

    Hardwiring the future

    A Cell & Gene production unit staffed by a highly trained team at Novartis will soon begin operating in Stein, Switzerland.

    From Our Labs
  • Retinal ganglion cells
    From Our Labs
    Eye CareNovartis Institutes for BioMedical ResearchOphthalmologyEye Disorders
    Jul 20, 2021

    What goes wrong with the window to the soul in glaucoma?

    Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.

    From Our Labs
  • A scientist using Lab2Lab
    From Our Labs
    Emerging TechnologyInnovationNovartis Institutes for BioMedical Research
    Sep 28, 2021

    How a 19th-century technology is speeding up drug discovery

    Pneumatic tube systems have existed for 150+ years and have transported everything from telegrams to aircraft parts. Now they’re being used in our labs.

    From Our Labs
  • Novartis scientists Edward Oakeley (left) and Mevion Oertli use a plasma screen to present their findings to Novartis researchers.
    From Our Labs
    Novartis Institutes for BioMedical ResearchReimagine MedicineNew Scientific DiscoveriesNext Generation SequencingScientific Research
    Jul 20, 2021

    Reimagining protein sequencing

    Three years after discussing how to reuse an old scientific measuring device, Novartis scientists are now testing this idea as part of an innovative research project.

    From Our Labs
  • Jean Silveri doing work
    From Our Labs
    Ethical BusinessNovartis Institutes for BioMedical ResearchWomen in ScienceWorking at NovartisCareers
    Jul 20, 2021

    Women in Science: Jean Silveri

    Jean Silveri shares key insights from her legal career.

    From Our Labs
  • Jennifer Allport-Anderson shares scientific insights with a colleague
    From Our Labs
    Heart FailureNovartis Institutes for BioMedical ResearchWomen in ScienceWorking at NovartisCareers
    Jul 20, 2021

    Women in Science: Jennifer Allport-Anderson

    Cardiovascular researcher Jennifer Allport-Anderson describes the personal qualities and decisions that have made her a successful leader.

    From Our Labs

Pagination

  • ‹ Previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • › Next page

Novartis

Working together
  • Patients and caregivers
  • Healthcare professionals
  • Researchers
  • Job seekers
  • Journalists
  • Investors
Topics
  • Eurovision
  • Access
  • ESG
  • SpeakUp
Explore
  • Pipeline
  • Products
  • Clinical trials
  • Partnering
  • Events
Therapeutic areas
  • Cardiovascular, renal and metabolic
  • Immunology
  • Neuroscience
  • Oncology
Footer Bottom
© 2025 Novartis AG
  • Terms of use
  • Privacy
  • Cookie settings
  • Contacts
  • Locations
  • Site map
  • Open source
  • Web accessibility
Novartis Site Directory
This site is intended for a global audience